The estimated Net Worth of Scott Dreyer is at least $12.2 Milion dollars as of 23 May 2024. Mr. Dreyer owns over 108,016 units of Collegium Pharmaceutical Inc stock worth over $3,833,652 and over the last 6 years he sold COLL stock worth over $6,385,027. In addition, he makes $1,976,910 as Executive Vice President a Chief Commercial Officer at Collegium Pharmaceutical Inc.
Scott has made over 14 trades of the Collegium Pharmaceutical Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 108,016 units of COLL stock worth $3,662,823 on 23 May 2024.
The largest trade he's ever made was selling 108,016 units of Collegium Pharmaceutical Inc stock on 23 May 2024 worth over $3,662,823. On average, Scott trades about 8,009 units every 66 days since 2018. As of 23 May 2024 he still owns at least 105,902 units of Collegium Pharmaceutical Inc stock.
You can see the complete history of Mr. Dreyer stock trades at the bottom of the page.
Scott Dreyer serves as Executive Vice President, Chief Commercial Officer of the Company. Mr. Dreyer has served as our Executive Vice President and Chief Commercial Officer since August 2018, and joined us in January 2018 as Senior Vice President, Sales, Marketing and Training. Prior to joining us, Mr. Dreyer served as the Senior Vice President, Sales, Marketing and Commercial Operations at The Medicines Company, a biopharmaceutical company, from September 2016 to December 2017; Vice President and Chief Marketing Officer – US at Biogen from June 2014 to September 2016; and Vice President, Business Development at Publicis Touchpoint Solutions, a healthcare commercialization company, from October 2013 to June 2014. Mr. Dreyer began his career in the pharmaceutical industry at Merck & Co., where he held roles of increasing responsibility from 1994 to 2013, including Vice President of Hospital and Oncology Sales from 2011 to 2012, and Vice President of Primary Care Sales from 2012 until 2013. Mr. Dreyer holds a B.S. in Biology from Messiah College in 1994.
As the Executive Vice President a Chief Commercial Officer of Collegium Pharmaceutical Inc, the total compensation of Scott Dreyer at Collegium Pharmaceutical Inc is $1,976,910. There are 1 executives at Collegium Pharmaceutical Inc getting paid more, with Joseph Ciaffoni having the highest compensation of $4,032,630.
Scott Dreyer is 47, he's been the Executive Vice President a Chief Commercial Officer of Collegium Pharmaceutical Inc since 2018. There are 15 older and 3 younger executives at Collegium Pharmaceutical Inc. The oldest executive at Collegium Pharmaceutical Inc is John Fallon, 72, who is the Independent Director.
Scott's mailing address filed with the SEC is C/O COLLEGIUM PHARMACEUTICAL, INC., 100 TECHNOLOGY CENTER DRIVE, STOUGHTON, MA, 02072.
Over the last 9 years, insiders at Collegium Pharmaceutical Inc have traded over $80,399,308 worth of Collegium Pharmaceutical Inc stock and bought 1,112,375 units worth $13,316,951 . The most active insiders traders include Group Holdings (Sbs) Adviso..., John Gordon Freund a David Hirsch. On average, Collegium Pharmaceutical Inc executives and independent directors trade stock every 35 days with the average trade being worth of $2,130,406. The most recent stock trade was executed by Shirley R. Kuhlmann on 5 September 2024, trading 20,225 units of COLL stock currently worth $773,809.
collegium pharmaceutical, inc. is a specialty pharmaceutical company developing and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. with a substantial number of patients suffering from chronic pain, collegium is committed to developing and commercializing a portfolio of products that address the growing problems associated with non-medical use, abuse and misuse of prescription products by leveraging the company’s proprietary deterx® technology platform. deterx technology can be used with drugs that are commonly abused such as opioids and amphetamines, as well as drugs that have a narrow therapeutic index that would benefit from protection against misuse such as breaking, crushing, grinding, or dissolving the product. the deterx technology platform is covered by u.s. and international patents and patent applications. collegium’s lead product candidate, xtampza er™, is an abuse-deterrent, ex
Collegium Pharmaceutical Inc executives and other stock owners filed with the SEC include: